To assess the clinical significance of TP53 loss in ETS-positive prostate cancer, we mined clinical outcome data in three datasets (Fig. 4C): (i) TCGA dataset of primary prostate cancer using endpoint of progression-free survival (3), (ii) MSKCC dataset of aggressive prostate cancer with endpoint of overall survival (42), and (iii) SU2C/PCF International Dream Team dataset of castrate-resistant prostate cancer (CRPC) with endpoint of overall survival (43, 44). This evidence concerns the gene TP53 and prostate cancer.